Intraperitoneal Paclitaxel Treatment for Patients with Pancreatic Ductal Adenocarcinoma with Peritoneal Dissemination Provides a Survival Benefit.
Tomohisa YamamotoSohei SatoiSo YamakiDaisuke HashimotoMitsuaki IshidaTsukasa IkeuraSatoshi HirookaYuki MatsuiShogen BokuShinji NakayamaKoh NakamaruNobuhiro ShibataUtae KatsushimaMitsugu SekimotoPublished in: Cancers (2022)
i.p.-PTX therapy provided improved survival in PDAC patients with peritoneal dissemination, and conversion surgery enhanced it in patients with favorable responses to chemotherapy. i.p.-PTX might become one of the treatment options to PDAC patients with peritoneal dissemination.